StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
CPIXCUMBERLAND PHARMACEUTICALS INC
stockpulse.co.kr
Nasdaq
$7.40▼ 13.85%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $110.9MShares out 15.0M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

5
  • 1d agoAfter-hours26.10.24 06:01
    8-KKey event#●●●#●●●

    CUMBERLAND PHARMACEUTICALS INCBullish

    Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban for patients with systemic sclerosis. The results support the safety and tolerability of ifetroban in this rare disease population.…more

    $7.40-13.85%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 9.11After-hours26.09.12 05:51
    8-K/AKey event

    CUMBERLAND PHARMACEUTICALS INC

    Cumberland Pharmaceuticals has determined to hold advisory votes on executive compensation every three years, following the results of the 2026 Annual Meeting of Shareholders held on April 21, 2026. This decision reflects the shareholder vote and subsequent discussions by the Board of Directors.…more

    $7.40-13.85%vs prev close
    View filingShare
  • 8.28After-hours26.08.29 06:08
    8-KKey event

    CUMBERLAND PHARMACEUTICALS INC

    Cumberland Pharmaceuticals has delayed the presentation of long-term safety and efficacy data for its Phase 2 FIGHT DMD trial of ifetroban, which was originally expected in August 2026. The company stated that the data is not yet available and intends to present it at a future date once it becomes accessible.…more

    $7.40-13.85%vs prev close
    View filingShare

4 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 1d agoAfter-hours26.10.24 05:09
    #●●●#●●●#●●●

    Cumberland Pharmaceuticals Reports Phase 2a Results for Ifetroban in Systemic Sclerosis…more

    Cumberland Pharmaceuticals confirmed the safety of ifetroban in its Phase 2a trial for systemic sclerosis, though limited disease progression hindered the ability to demonstrate efficacy. The company plans to continue evaluating treatment effects through upcoming biomarker studies and cardiac imaging.…more

    $7.40-13.85%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga